| Bioactivity | Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC50 value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells[1]. |
| Invitro | Bcl-2-IN-9 (compound 6e) (10 μM, 48 hours) inhibits HL-60 cells in vitro[1].Bcl-2-IN-9 (compound 6e) (10 μM, 48 hours) shows low cytotoxic effects against WI-38 cells with cell viability of 91%[1].Bcl-2-IN-9 (compound 6e) (10 μM, 48 hours) displays a high selectivity against leukemia cells[1].Bcl-2-IN-9 (compound 6e) (10 μM) mediates apoptotic by down-regulating expression of Bcl-2 and causing chromatin compaction and nuclear fragmentation[1]. Cell Viability Assay[1] Cell Line: |
| Name | Bcl-2-IN-9 |
| CAS | 2490542-33-9 |
| Formula | C27H31N7O3S |
| Molar Mass | 533.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Bcl-2-IN-9
CAS: 2490542-33-9 F: C27H31N7O3S W: 533.65
Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC50 value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.